Literature DB >> 12774921

Oxidative stress and the myelodysplastic syndromes.

Morag J Farquhar1, David T Bowen.   

Abstract

The evolution of higher organisms from anaerobic to aerobic living has promoted an elaborate mechanism of defense against potentially toxic oxidants. Many environmental toxicants implicated in the pathogenesis of myelodysplastic syndromes (MDS), including benzene and ionizing radiation, exert toxicity via pro-oxidant mechanisms. The emerging data suggest a probable genetic susceptibility to environmental carcinogenesis through functional polymorphic variants in enzymes that metabolize toxicants and/or protect against oxidative stress. The most studied enzyme is NAD(P)H:quinone oxidoreductase (NQO1). CD34+ cells from individuals homozygous for the NQO1 C609T nonfunctional allelic variant are incapable of enzyme induction following exposure to benzene, thus potentially increasing the hematotoxicity of benzene metabolites. Serologic and molecular markers of oxidative stress are present in many patients with MDS and include an increased concentration of the lipid peroxidation product malondialdehyde and the presence of oxidized bases in CD34+ cells. Potential mechanisms of oxidative stress include mitochondrial dysfunction via iron overload and mitochondrial DNA mutation, systemic inflammation, and bone marrow stromal defects. The biological activity of the antioxidant aminothiol amifostine in vivo suggests that these pathways may be meaningful targets for future therapy in MDS patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12774921     DOI: 10.1007/bf02982641

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  87 in total

1.  Human CD34+ cells do not express glutathione S-transferases alpha.

Authors:  M Czerwinski; H P Kiem; J T Slattery
Journal:  Gene Ther       Date:  1997-03       Impact factor: 5.250

2.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow.

Authors:  A Jonásova; R Neuwirtová; J Cermák; V Vozobulová; K Mociková; M Sisková; I Hochová
Journal:  Br J Haematol       Date:  1998-02       Impact factor: 6.998

3.  Acute leukemia due to chronic exposure to benzene.

Authors:  M Aksoy; K Dinçol; S Erdem; G Dinçol
Journal:  Am J Med       Date:  1972-02       Impact factor: 4.965

4.  Increase in number of bone marrow macrophages in patients with myelodysplastic syndromes.

Authors:  M Kitagawa; R Kamiyama; T Kasuga
Journal:  Eur J Haematol       Date:  1993-07       Impact factor: 2.997

5.  Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone.

Authors:  N Rothman; M T Smith; R B Hayes; R D Traver; B Hoener; S Campleman; G L Li; M Dosemeci; M Linet; L Zhang; L Xi; S Wacholder; W Lu; K B Meyer; N Titenko-Holland; J T Stewart; S Yin; D Ross
Journal:  Cancer Res       Date:  1997-07-15       Impact factor: 12.701

6.  Smoking and myelodysplastic syndromes.

Authors:  J Björk; M Albin; N Mauritzson; U Strömberg; B Johansson; L Hagmar
Journal:  Epidemiology       Date:  2000-05       Impact factor: 4.822

7.  Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration.

Authors:  C M Peddie; C R Wolf; L I McLellan; A R Collins; D T Bowen
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

8.  Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes.

Authors:  M Kitagawa; M Takahashi; S Yamaguchi; M Inoue; S Ogawa; K Hirokawa; R Kamiyama
Journal:  Leukemia       Date:  1999-05       Impact factor: 11.528

9.  A case-control study of myelodysplastic syndromes among Japanese men and women.

Authors:  M Ido; C Nagata; N Kawakami; H Shimizu; Y Yoshida; T Nomura; H Mizoguchi
Journal:  Leuk Res       Date:  1996-09       Impact factor: 3.156

10.  Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia.

Authors:  J P Maciejewski; C Selleri; T Sato; S Anderson; N S Young
Journal:  Br J Haematol       Date:  1995-09       Impact factor: 6.998

View more
  28 in total

1.  Mouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotype.

Authors:  Charlie Mantel; Steven Messina-Graham; Akira Moh; Scott Cooper; Giao Hangoc; Xin-Yuan Fu; Hal E Broxmeyer
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

2.  S-glutathionylated serine proteinase inhibitors as plasma biomarkers in assessing response to redox-modulating drugs.

Authors:  Christina L Grek; Danyelle M Townsend; Joachim D Uys; Yefim Manevich; Woodrow J Coker; Christopher J Pazoles; Kenneth D Tew
Journal:  Cancer Res       Date:  2012-03-08       Impact factor: 12.701

Review 3.  Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Alexander Scarth Watson; Monika Mortensen; Anna Katharina Simon
Journal:  Cell Cycle       Date:  2011-06-01       Impact factor: 4.534

Review 4.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

5.  Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Franklin Hendrick; Erika Friedmann; Maria R Baer; Steven D Gore; Medha Sasane; Carole Paley; Amy J Davidoff
Journal:  J Comp Eff Res       Date:  2015-08       Impact factor: 1.744

Review 6.  Reactive oxygen species in eradicating acute myeloid leukemic stem cells.

Authors:  Hui Zhang; Hai Fang; Kankan Wang
Journal:  Stem Cell Investig       Date:  2014-06-07

7.  Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells.

Authors:  Un-Ho Jin; Yating Cheng; Beiyan Zhou; Stephen Safe
Journal:  Mol Pharmacol       Date:  2017-03-08       Impact factor: 4.436

8.  NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Authors:  Peter L Greenberg; Eyal Attar; John M Bennett; Clara D Bloomfield; Carlos M De Castro; H Joachim Deeg; James M Foran; Karin Gaensler; Guillermo Garcia-Manero; Steven D Gore; David Head; Rami Komrokji; Lori J Maness; Michael Millenson; Stephen D Nimer; Margaret R O'Donnell; Mark A Schroeder; Paul J Shami; Richard M Stone; James E Thompson; Peter Westervelt
Journal:  J Natl Compr Canc Netw       Date:  2011-01       Impact factor: 11.908

9.  Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome.

Authors:  Yang Jo Chung; Carine Robert; Sheryl M Gough; Feyruz V Rassool; Peter D Aplan
Journal:  Leuk Res       Date:  2013-08-16       Impact factor: 3.156

Review 10.  Oxidases and reactive oxygen species during hematopoiesis: a focus on megakaryocytes.

Authors:  Alexia Eliades; Shinobu Matsuura; Katya Ravid
Journal:  J Cell Physiol       Date:  2012-10       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.